<p>Indian Immunologicals Ltd, a city-based facility under the National Dairy Development Board, has announced its plans to begin the production of drug substance meant for Covid-19 vaccine Covaxin from June 15, and despatch the first batch to Bharat Biotech by July. IILs Managing Director K Anand Kumar in a release on Friday said the firm is expected to produce the drug substance initially for 2-3 million doses per month.</p>.<p>It will be scaled up to 7 million later in the year and eventually to 15 million. To further increase the Covid-19 vaccine manufacturing capacity, Bharat Biotech had said itpartnered with IIL to make the drug substance for Covaxin.</p>.<p>The technology transfer process was well underway and IILhas the capabilities and expertise to manufacture inactivated viral vaccines at commercial scale and under biosafety containment, the drug had said.</p>.<p>Kumar said IIL is converting its Karkapatla manufacturing unit near here into a Biosafety Level -3 (BSL3) facility for the production of the drug substance and also taking up construction of another block. IIL is also working on another Covid -19 vaccine and the animal trials are underway and is expected to come out next year for human vaccination, he noted.</p>
<p>Indian Immunologicals Ltd, a city-based facility under the National Dairy Development Board, has announced its plans to begin the production of drug substance meant for Covid-19 vaccine Covaxin from June 15, and despatch the first batch to Bharat Biotech by July. IILs Managing Director K Anand Kumar in a release on Friday said the firm is expected to produce the drug substance initially for 2-3 million doses per month.</p>.<p>It will be scaled up to 7 million later in the year and eventually to 15 million. To further increase the Covid-19 vaccine manufacturing capacity, Bharat Biotech had said itpartnered with IIL to make the drug substance for Covaxin.</p>.<p>The technology transfer process was well underway and IILhas the capabilities and expertise to manufacture inactivated viral vaccines at commercial scale and under biosafety containment, the drug had said.</p>.<p>Kumar said IIL is converting its Karkapatla manufacturing unit near here into a Biosafety Level -3 (BSL3) facility for the production of the drug substance and also taking up construction of another block. IIL is also working on another Covid -19 vaccine and the animal trials are underway and is expected to come out next year for human vaccination, he noted.</p>